Description: MediPharm Labs, through its subsidiary, is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs, through its subsidiary, provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.
Home Page: www.medipharmlabs.com
LABS Technical Analysis
151 John Street
Barrie,
ON
L4N 2L1
Canada
Phone:
705 719 7425
Officers
| Name | Title |
|---|---|
| Mr. Keith Strachan | Co-Founder & Pres |
| Mr. Greg Hunter | Chief Financial Officer |
| Mr. David A. Pidduck | CEO & Director |
| Mr. Patrick McCutcheon | Founder |
| Mr. Saravan Subramaniam | VP of Operations & Supply Chain |
| Mr. Geoffrey Marr | Exec. VP & Gen. Counsel |
| Mr. Brett Moon | VP of Sales |
| Mr. Kirk Binns | Exec. VP of Global Accounts |
| Mr. Nigel Dewsbury | Head of Quality |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 27.4725 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3711 |
| Price-to-Sales TTM: | 0.9458 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 190 |